WO2022232315A8 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
WO2022232315A8
WO2022232315A8 PCT/US2022/026596 US2022026596W WO2022232315A8 WO 2022232315 A8 WO2022232315 A8 WO 2022232315A8 US 2022026596 W US2022026596 W US 2022026596W WO 2022232315 A8 WO2022232315 A8 WO 2022232315A8
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
way
treat
present
compounds
Prior art date
Application number
PCT/US2022/026596
Other languages
French (fr)
Other versions
WO2022232315A1 (en
Inventor
Brandon CARNEY
Andrew Riley
Original Assignee
Quaero Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quaero Pharmaceuticals Llc filed Critical Quaero Pharmaceuticals Llc
Publication of WO2022232315A1 publication Critical patent/WO2022232315A1/en
Publication of WO2022232315A8 publication Critical patent/WO2022232315A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides synthetic peptides and substituted peptides that exhibit potent NaV1.7 inhibition. The present invention provides compounds, methods and compositions effective to image nerve anatomy or physiology, either by PET imaging or by fluorescent optical imaging, to treat pain by way of NaV1.7 inhibition, to treat itching by way of NaV1.7 inhibition, and to treat cancer by way of NaV1.7 inhibition.
PCT/US2022/026596 2021-04-27 2022-04-27 Compounds WO2022232315A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163180208P 2021-04-27 2021-04-27
US63/180,208 2021-04-27

Publications (2)

Publication Number Publication Date
WO2022232315A1 WO2022232315A1 (en) 2022-11-03
WO2022232315A8 true WO2022232315A8 (en) 2023-04-20

Family

ID=83847320

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/026596 WO2022232315A1 (en) 2021-04-27 2022-04-27 Compounds

Country Status (1)

Country Link
WO (1) WO2022232315A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
UY35397A (en) * 2013-03-12 2014-10-31 Amgen Inc POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7
CA2989353A1 (en) * 2015-06-29 2017-01-05 The University Of British Columbia B1sp fusion protein for the treatment of cancer

Also Published As

Publication number Publication date
WO2022232315A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
AU2019231551A8 (en) Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones
EA202193338A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS
BR112022012641A2 (en) SUBSTITUTED TRICYCLIC COMPOUNDS
CR20200358A (en) Compounds for the treatment of kinase-dependent disorders
MX2021013854A (en) Compounds for treating huntington's disease.
UY38742A (en) 2,3,5-PYRAZOLO [1,5-A] PYRIMIDINE TRISUSTITUED COMPOUNDS
CR20220626A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
MX2022013856A (en) Htt modulators for treating huntington's disease.
MX2021008094A (en) Methods and compositions for treating cancer.
CR20220207A (en) Therapeutic compounds and methods of use
SA520412488B1 (en) Compounds for The Treatment of Kinase-Dependent Disorders
MA54133B1 (en) Aminopyrazine diol compounds used as pi3k-y inhibitors
ZA202301275B (en) Indole compounds as androgen receptor modulators
EA200600071A1 (en) Derivatives of N-phenylpyrazine and Methods for the Prevention or Treatment of Diseases Associated with 5HT-Receptor
EA202092125A1 (en) ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
MX2023008589A (en) Gcn2 modulating compounds and uses thereof.
BR112022021743A2 (en) COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34
BR112022020147A2 (en) COMPOUNDS TO TREAT HUNTINGTON'S DISEASE
EA202092608A1 (en) Spiropiperidine allosteric modulators of nicotine acetylcholine receptors
WO2022232315A8 (en) Compounds
MX2022002446A (en) Perk inhibiting pyrrolopyrimidine compounds.
MX2023011829A (en) Uracil derivatives as trpa1 inhibitors.
MX2022012632A (en) Use of bromodomain inhibitors for treatment of huntington's disease.
MX2022005976A (en) Adenosine receptor antagonist compounds.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22796673

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22796673

Country of ref document: EP

Kind code of ref document: A1